Fountain Healthcare Partners has held a final close for its third life science venture capital fund at €118 million, exceeding the initial target of €100 million. Fountain Healthcare Partners III will primarily focus on specialty pharmaceuticals, biotechnology and medical devices in Europe, with some investments also expected in the US. The firm plans to make 10 to 12 investments from the fund.
Investors in the fund include the European Investment Fund, the Ireland Strategic Investment Fund and the Allied Irish Bank. The remaining capital was sourced from funds of funds, corporate investors, and family offices.
If you do not receive this within five minutes, please try to sign in again. If the problem persists, please email: